USFDA14 Sept 2026, 08:00 pm
Piramal Pharma's Morpeth Facility Receives 7 Observations from US FDA
AI Summary
Piramal Pharma Limited's manufacturing facility in Morpeth, UK, was inspected by the US FDA for Good Manufacturing Practices (GMP) between September 3rd and September 11th, 2026. The inspection resulted in the issuance of a Form-483 with seven observations. These observations pertain to enhancements in the company's practices, procedures, and documentation. Piramal Pharma is actively working on a comprehensive response to be submitted to the US FDA within the designated timeframe, reaffirming its commitment to maintaining high compliance standards.
Key Highlights
- US FDA inspected Piramal Pharma's Morpeth, UK facility.
- Inspection yielded 7 observations in a Form-483.
- Observations relate to practices, procedures, and documentation.
- Company is preparing a detailed response to US FDA.
- Piramal Pharma committed to highest compliance standards.
Price Impact
More from PPLPHARMA